Inhibitor Therapeutics (INTI) Other Accumulated Expenses (2013 - 2022)

Inhibitor Therapeutics (INTI) has 10 years of Other Accumulated Expenses data on file, last reported at $65000.0 in Q3 2022.

• Quarterly Other Accumulated Expenses rose 96.97% year-over-year to $65000.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $65000.0 (up 96.97% YoY) and the FY2021 annual result came in at $53000.0, up 110.95% from the prior year.
• Other Accumulated Expenses was little changed at $65000.0 in Q3 2022, from $65000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $215876.0 in Q4 2018 to a low of $9310.0 in Q1 2021.
• A 5-year average of $61694.4 and a median of $44442.0 in 2018 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2019 — Other Accumulated Expenses tumbled 93.36% — and 2020, when it jumped 743.04%.
• Tracing INTI's Other Accumulated Expenses over 5 years: stood at $215876.0 in 2018, then plunged by 93.36% to $14339.0 in 2019, then surged by 75.21% to $25124.0 in 2020, then soared by 110.95% to $53000.0 in 2021, then increased by 22.64% to $65000.0 in 2022.
• The last three Other Accumulated Expenses figures came in at $65000.0 (Q3 2022), $65000.0 (Q2 2022), and $57000.0 (Q1 2022), per Business Quant data.